Considering the presence or absence of receptors results in classification of breast cancers into four therapeutic groups in clinical settings [11]: estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2 amplified (HER2+) and triple negative. Here, PGR is linked to breast cancer.